Haeberlein SB, Gheuens S, Chen T, et al. Aducanumab 36-month data from PRIME: a randomized, double-blind, placebocontrolled phase 1b study in patients with prodromal or mild Alzheimer’s disease. AAN 2018, S2.004.
ZonMw investeert in verbeteren leefstijl na beroerte
jan 2024 | Myocardinfarct, Neuro-vasculair